On Invalid Date, Cyclo Therapeutics (NASDAQ: CYTH) reported Q4 2023 earnings per share (EPS) of -$0.23, up 61.02% year over year. Total Cyclo Therapeutics earnings for the quarter were -$5.64 million. In the same quarter last year, Cyclo Therapeutics's earnings per share (EPS) was -$0.59.
As of Q1 2024, Cyclo Therapeutics's earnings has grown year over year. Cyclo Therapeutics's earnings in the past year totalled -$20.06 million.
What is CYTH's earnings date?
Cyclo Therapeutics's earnings date is Invalid Date. Add CYTH to your watchlist to be reminded of CYTH's next earnings announcement.
What was CYTH's revenue last quarter?
On Invalid Date, Cyclo Therapeutics (NASDAQ: CYTH) reported Q4 2023 revenue of $311.40 thousand up 66.7% year over year. In the same quarter last year, Cyclo Therapeutics's revenue was $186.80 thousand.
What was CYTH's revenue growth in the past year?
As of Q1 2024, Cyclo Therapeutics's revenue has grown -21.76% year over year. This is 31.48 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.72%. Cyclo Therapeutics's revenue in the past year totalled $1.08 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.